Sinogal

Quick links to important sections

Sinogal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinogal

Property Description
Active ingredient Ampicillin, Sulbactam
Form Powder for Injection (Injectable Preparation)
Pharmacological class Penicillins / beta-Lactamase Inhibitor combination
Common use Systemic treatment of serious bacterial infections
Origin Synthetic

What Type of Medicine is Sinogal?

Sinogal is a sophisticated, Broad-spectrum Antibacterial Agent classified pharmacologically as a beta-Lactam antibiotic combined with a beta-Lactamase Inhibitor. This medicine is a synthetic, fixed-dose combination product that contains the two distinct active ingredients, Ampicillin and Sulbactam. Ampicillin, a derivative of the penicillin nucleus, belongs to the aminopenicillin subgroup. The formulation is clinically recognized for its utility against pathogens that have developed resistance to Ampicillin alone, extending the effective use of this penicillin derivative.

Composition: Ampicillin and Sulbactam's Active Roles

The medicine’s efficacy stems from the essential synergy between its two active components, Ampicillin and Sulbactam. Ampicillin functions as the primary antibacterial agent by disrupting the formation of the bacterial cell wall, a crucial process that leads to the death of the microorganism. The problem is that many resilient bacteria produce destructive beta-lactamase enzymes that inactivate Ampicillin. The second component, Sulbactam, is the dedicated beta-Lactamase Inhibitor; its distinct feature is to block these bacterial defense enzymes irreversibly. This protective action is critical because it ensures Ampicillin can remain biologically active, thereby extending the antibacterial spectrum to include many strains that would otherwise be resistant.

General Purpose and Pharmaceutical Form

The medicine's general purpose is to provide powerful, systemic antimicrobial therapy for infections caused by susceptible organisms, with a focus on those resistant to Ampicillin alone. To achieve the necessary therapeutic levels rapidly throughout the body, Sinogal is supplied as a sterile Powder for Injection—a dry preparation that requires reconstitution with an aqueous diluent immediately before use. This presentation defines the Parenteral route of administration (Intravenous or Intramuscular), which ensures high bioavailability and positions the prescription-only (Rx) formulation for severe infections requiring close medical supervision.

Regulatory References

  1. MedlinePlus Drug Information
  2. NIH StatPearls

What side effects are possible with Sinogal?

Sinogal: Possible Side Effects and Safety Information

All medicines are associated with a known safety profile, which is established through clinical trials and ongoing post-marketing surveillance. This profile is documented by regulatory agencies to inform healthcare professionals and patients about potential adverse reactions and necessary precautions.

Authoritative regulatory documentation specific to Sinogal (such as official prescribing information or summaries of product characteristics) detailing its precise safety profile is not currently available in the public record of major global health authorities (e.g., the FDA or EMA).

If a complete regulatory safety summary were available, it would typically classify adverse reactions by frequency and body system, as illustrated below. This structured approach helps assess the drug's overall risk-benefit balance:

Classification Expected Regulatory Detail
Very Common Reactions occurring in ge 1 in 10 patients.
Common Reactions occurring in ge 1 in 100 to < 1 in 10 patients.
Uncommon to Rare Less frequent reactions, down to < 1 in 1,000 or < 1 in 10,000 patients.

Regulatory documents also define serious and clinically significant adverse reactions, which may necessitate immediate medical attention or discontinuation of the therapy. These often include warnings regarding potential organ toxicity, severe allergic responses, or specific conditions like cardiovascular events or hematologic disorders.

Furthermore, official safety information usually identifies safety-related restrictions and limitations, such as contraindications for use in specific patient populations (e.g., those with severe liver or kidney impairment, or during pregnancy/lactation) and requirements for ongoing laboratory monitoring. The official regulatory basis for this profile would confirm which government authority (e.g., the FDA, EMA) approved the final safety label.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Ampicillin/Sulbactam (Sinogal) as potentially leading to neurological adverse reactions, including convulsions (seizures). These serious manifestations are linked to the attainment of high concentrations of beta-lactam components in the cerebrospinal fluid.

Overdose risk is heightened in patients with impaired renal function because the body's ability to clear both active components is reduced, leading to prolonged systemic exposure and an increased risk of toxicity.

Required Emergency Actions

The regulatory profile mandates immediate emergency medical attention upon suspicion of an overdose. Urgent action is required if an individual is displaying severe symptoms such as having a seizure, experiencing trouble breathing, or if they have collapsed or cannot be awakened.

Management and Clearance

Treatment for overdose is documented as being symptomatic and consists of providing supportive care. A procedural step listed in the official management plan is the discontinuation of the medicine. The official labeling confirms that the Ampicillin component may be removed from circulation by hemodialysis. A specific antidote for this medicine is not documented in the regulatory prescribing information.

Therapeutic Uses of Sinogal

What Sinogal Treats: Main Uses and Benefits

Sinogal is applied across domains where additional symptomatic support is needed. It is relevant in contexts marked by increased discomfort or tension. The use of medications for symptomatic support in these contexts is a recognized part of management. Sinogal may be part of symptomatic management for acute, episodic, and fluctuating manifestations that create noticeable functional strain.


Key Areas of Symptom Support

Sinogal is considered relevant for easing symptom clusters that may become intense or disruptive, including symptoms related to heightened physiological activity and physical discomfort. It is applied during phases of increased distress or discomfort. This supports the patient, helping them cope more steadily with symptom fluctuations. It is commonly used when short-term symptomatic assistance is needed for conditions characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations.


Quick Fact: Support for Symptomatic Periods

Sinogal helps address symptom clusters that may become intense or disruptive, and contributes to easing the overall symptom load during periods of heightened symptoms.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Sinogal

Official regulatory documents strictly define the population that can safely use Sinogal (Ampicillin/Sulbactam) by establishing absolute prohibitions and specific patient limitations.


Category Regulatory Status and Rules
Absolute Contraindications Use is prohibited for individuals with a history of a serious hypersensitivity reaction to any beta-lactam antibacterial drug (penicillins, cephalosporins, ampicillin, or sulbactam). The medicine is also contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction specifically associated with its previous use.
Pediatric Eligibility Safety and efficacy have not been established in children younger than 1 year of age for certain labeled uses. Caution is required for neonates (younger than one week) and premature infants.
Condition Restrictions The medicine is not recommended for use in patients with Infectious Mononucleosis. Use requires caution in patients with existing impaired renal function or pre-existing liver disease due to the risk of slower clearance or recurrence of drug-induced injury.
Pregnancy/Lactation Pregnancy: Use is restricted and should only occur if clearly needed, as safety in human pregnancy has not been definitively established. Lactation: Use is generally acceptable but requires caution as both components are excreted in human milk.

What should I know about interactions with other medicines?

Documented Interactions with Medicines

The official regulatory profile for Sinogal (Ampicillin/Sulbactam) is structured around interactions that affect systemic exposure, therapeutic activity, and administration logistics.

  • Probenecid: Co-administration with this uricosuric agent results in higher and more prolonged serum levels of both active ingredients by reducing their clearance via renal tubular secretion.
  • Bacteriostatic Agents: Drugs such as Tetracyclines, Chloramphenicol, Sulfonamides, and Erythromycin may cause pharmacodynamic interference that can oppose the bactericidal action of the penicillin component.
  • Allopurinol: Concurrent administration is documented to substantially increase the incidence of skin rashes compared to the use of Ampicillin-containing medicines alone.
  • Methotrexate: Penicillins may decrease the renal clearance of Methotrexate, potentially leading to increased Methotrexate concentrations and toxicity.
  • Oral Contraceptives: Case reports have noted a reduction in the effectiveness of estrogen-containing oral contraceptives.

Mandatory Separation Rules

Aminoglycosides must be administered at separate sites at least one hour apart from this medicine. This constraint is required due to documented in vitro mutual inactivation between the two classes of injectable antibacterials.

Population and Condition Constraints

The use of this medicine is contraindicated in patients with Infectious Mononucleosis due to a high incidence of rash. Additionally, in patients with impaired renal function (creatinine clearance leq 30 mL/minute), the elimination kinetics of both active components are similarly affected, leading to slower removal from the body.

Mechanism of Action

The mechanism of action for Sinogal (Ampicillin/Sulbactam) is a combined pharmacological strategy that employs two distinct components to achieve lethal disruption of bacterial organisms.

Irreversible Structural Disruption of Bacteria

The component, Ampicillin, exerts its effect by targeting Penicillin-Binding Proteins (PBPs)—enzymes essential for building the rigid structural framework (peptidoglycan) of the bacterial cell wall. By irreversibly inhibiting these proteins, the drug halts the final stages of cell wall synthesis, leading to a catastrophic structural failure and the rapid, osmotic-driven breakdown (lysis) of the target bacterium.

Neutralizing Bacterial Defense Mechanisms

The co-component, Sulbactam, acts as a dedicated suicide inhibitor of beta-Lactamase enzymes, which are produced by resistant bacteria to chemically destroy Ampicillin. Sulbactam irreversibly binds and neutralizes these defense enzymes, effectively shielding Ampicillin from destruction. This protective mechanism restores the activity of Ampicillin's cell-wall disruption mechanism, extending the drug's overall activity by restoring Ampicillin's function against strains that produce beta-Lactamase.

Dosage and Administration Information

Official Administration Guidelines for Sinogal (Levomepromazine)

Sinogal must be used strictly according to the prescribing information. Administration routes include oral (tablets or solution), intramuscular (IM) injection, intravenous (IV) injection, and continuous subcutaneous (SC) infusion. The required route and dosage form are determined by the treating physician based on the patient's condition and setting.

Dosing and Scheduling

Doses are highly variable, ranging from 3 mg up to 1000 mg daily for severe cases. The total daily oral dose is generally divided into two or three doses, with the largest portion taken at bedtime to mitigate potential daytime sedation. Dosing for elderly patients and children must begin at a lower initial dose and is subject to strict maximum limits.

Preparation and Special Conditions

Administration Route Preparation / Condition
IV Administration The concentrated solution must be diluted with an equal volume of normal saline (0.9% sodium chloride) immediately prior to injection.
SC Infusion The dose must be diluted with a calculated volume of normal saline for continuous administration via a syringe driver over 24 hours.
Post-Injection/High Dose Patients must be kept in bed (recumbent) for at least one hour after any parenteral (IM/IV) dose or a large initial oral dose.

These guidelines define the mandatory preparation steps, timing rules, and specific post-administration monitoring required for the drug’s proper use as outlined in professional medical documentation.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sinogal (Ampicillin/Sulbactam)

This section provides an overview of the official research, clinical trials, and scientific studies conducted for Sinogal. This information describes the types of research that exist and what was measured by investigators, but it does not provide clinical advice or personal recommendations.


Evidence for Use in Common Approved Infections (Skin, Abdomen, Gynecological)

Studies have examined Sinogal for infections, including those affecting the skin and soft tissues (SSSI) or those inside the abdomen. Researchers evaluated the medicine in short-term randomized controlled trials (RCTs) and comparative studies, primarily exploring outcomes such as the evolution of symptoms related to physical discomfort and the measured reduction or eradication of the infection-causing bacteria. Findings described patterns related to the measured reduction of bacteria and the evolution of symptoms in the observed populations.

Evidence for Use Against Highly Resistant Pathogens (e.g., Acinetobacter baumannii)

For highly challenging infections, research largely consists of observational studies and systematic reviews that monitored outcomes in small, often critically ill, populations. Observational data show patterns related to clinical changes measured during the study period. However, this evidence is considered more limited because the results may be influenced by the patient's critical health status. Data for these groups are still emerging.


What is Still Uncertain or Limited in the Research Record

The research base has specific limitations. First, the scientific literature notes that while core indications were evaluated in RCTs, sample sizes were modest in some of the older trials. Second, the scientific literature highlights that follow-up durations were limited to the period immediately after treatment, meaning long-term effects are not fully established across all uses. Finally, the evidence for use against multi-drug resistant organisms often lacks large-scale, prospective RCTs, and those subgroup findings are uncertain.

Key Studies & References

  1. Ampicillin and Sulbactam (StatPearls - NIH National Library of Medicine).

Frequently Asked Questions (FAQ)

Common questions about Sinogal (FAQ)

Q: What are the most commonly reported side effects of Sinogal?

According to official product information, the most frequently reported side effects observed in clinical trials are diarrhea and rash. Patients have also reported pain at the injection site. This information is derived from systematic data collection during clinical trials and ongoing safety monitoring.


Q: Can Sinogal cause weight gain or loss?

Weight changes are generally not listed among the commonly reported side effects of Sinogal. However, official information indicates that certain serious side effects related to liver injury can sometimes involve symptoms such as loss of appetite and nausea. These occurrences are uncommon, and any persistent or concerning changes are aspects for patients to discuss with their healthcare provider.


Q: Is it normal to feel a little dizzy when first starting Sinogal?

Dizziness has been reported as an adverse reaction during the ongoing post-marketing experience with this medicine. This means that while it may not be the most common effect, it is a known possibility documented in official records. If this dizziness is experienced, it is an effect that should be noted for discussion with the healthcare provider supervising the treatment.


Q: Can Sinogal affect my sleep patterns?

While the medicine's label does not commonly list insomnia or direct sleep pattern changes, official product information has noted effects that could indirectly influence sleep. Specifically, mild effects such as fatigue and general malaise (a feeling of discomfort or illness) have been reported in a small percentage of patients during clinical studies.


Q: Does Sinogal affect fertility or conception?

Studies in animals have generally not revealed evidence of harm to the developing fetus. However, there are no adequate, well-controlled studies specifically on human fertility or in pregnant women. Official guidance indicates that its use during pregnancy is determined by a healthcare provider after evaluating the clinical need and potential risk profile.


Q: How long does Sinogal stay in your system after stopping treatment?

Regulatory documents describe the pharmacokinetics of the drug. The half-life (the time it takes for half the drug to be cleared from the bloodstream) is approximately one hour for the ampicillin component and slightly longer for the sulbactam component. It is noted that the clearance rate is slower in individuals who have impaired kidney function.


Q: Does Sinogal interact with birth control pills?

Yes, official regulatory documents state that case reports have noted a reduction in the effectiveness of estrogen-containing oral contraceptives when taken with penicillin antibiotics, which includes Sinogal. The interaction potential with birth control is an important topic for discussion with the prescribing healthcare provider.


Q: What is the guidance for using Sinogal in people with pre-existing liver problems?

Official information advises that caution is required for patients who have pre-existing liver disease. Furthermore, the medicine is strictly contraindicated (prohibited) if a patient has a history of cholestatic jaundice or hepatic impairment specifically linked to the previous use of this medicine.


Q: What are the severe but rare side effects of Sinogal?

Severe and potentially life-threatening reactions are noted in official warnings. These include severe allergic reactions (anaphylaxis) and serious skin disorders such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS syndrome. Other serious reactions that have been reported can involve liver toxicity (hepatitis or jaundice).


Q: Does taking Sinogal increase or decrease my appetite?

Appetite changes are not listed as a common reaction in clinical trials. However, a loss of appetite is noted in official warnings as a possible sign of developing liver problems, which is a severe side effect that requires professional medical evaluation.


Q: Is there a link between Sinogal and mental clarity/fog?

Official information reports adverse effects on the central nervous system. These reactions include dizziness and, rarely, convulsions (seizures). Headache has also been reported in a small percentage of patients during clinical trials, and these effects can indirectly influence mental clarity.


Q: How is Sinogal stored (room temperature, fridge, etc.)?

The sterile dry powder must be stored at controlled room temperature, typically between 20 C and 25 C (68 F to 77 F). The liquid solution must be prepared (reconstituted) immediately before administration and used within a short, specific time period defined by the product label, as it is not stable for long-term storage.


Q: What are the signs that Sinogal is starting to work for me?

Patient information published by government health authorities indicates that individuals receiving treatment should generally expect to begin feeling better within the first few days of starting the medicine. A noticeable improvement in the symptoms of the infection is the primary expected sign of the treatment working.


Q: How quickly should I expect to feel the effects of Sinogal?

Official patient guidance suggests that due to its method of action against bacteria, individuals should begin to feel better within the first few days of treatment. Because this is an injectable preparation, it delivers the medicine rapidly, and symptom improvement is an expected early sign.


Q: What happens if I miss a dose of Sinogal?

Official guidance emphasizes that the patient should contact their healthcare provider or pharmacist for guidance on adjusting the schedule immediately if a scheduled dose is missed. Official patient counseling information typically advises against taking a double dose to compensate for a missed dose.

How should Sinogal be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory guidelines define specific conditions for storing and disposing of Sinogal (Ampicillin/Sulbactam Powder for Injection) to ensure product integrity and public safety. These instructions must be strictly followed:


Storage Conditions

Requirement Instruction
Temperature Limit (Dry Powder) Store the sterile dry powder in its original vial at temperatures not exceeding 30 C (86 F).
Child Protection KEEP ALL MEDICINES OUT OF REACH OF CHILDREN.

Disposal and Stability

Regulatory labeling establishes that the reconstituted solution is For Single Use Only. Any remaining portion or unused liquid must be discarded immediately after use, as the product is not stable for later use. Disposal of expired or unused medication should strictly adhere to local, state, and federal pharmaceutical waste guidelines. Drain disposal is not recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinogal found in:

A-Z Index: